Tivdak® (tisotumab vedotin-tftv)
for Cervical Cancer

Tivdak (tisotumab vedotin-tftv) is an injectable medicine used to treat adults with cervical cancer that has returned or spread after chemotherapy. Administered by a healthcare provider every 3 weeks as an intravenous infusion, Tivdak is an antibody-drug conjugate (ADC). The antibody targets the tissue factor (TF) protein on cancer cells, while the attached drug, MMAE, enters the cells, preventing division and causing cancer cell death.

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Cervical Cancer